Indian pharma see no threat from Donald Trump's policies

In his press conference, Trump targeted drug makers and vowed to bring back production in the US

The proposed changes in the US healthcare policies will have minimal impact on Indian companies, drug makers and sector experts said on Thursday.

On Wednesday, US president-elect Donald Trump announced he will repeal and replace Obamacare Act, bring back pharma jobs to the US and introduce a new bidding procedure for Medicare, the government-backed social insurance programme.

Pharma companies stocks fell 1-3% during the opening trade on the BSE on Thursday but recouped the losses and sector experts blamed the drop in price to an overreaction.

"The Indian pharma industry has contributed significantly to contain and bring down healthcare costs